BeyondSpring Inc BYSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.46
- Day Range
- $0.48–0.57
- 52-Week Range
- $0.42–2.44
- Bid/Ask
- $0.50 / $0.59
- Shares Outstanding
- 41.12M
- Market Cap
- $21.57M
- Volume/Avg
- 25,923 / 833,522
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 44
Valuation
|
Metric
|
BYSI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BYSI
|
|---|---|
Quick Ratio | 0.46 |
Current Ratio | 0.70 |
Interest Coverage | — |
Quick Ratio
BYSI
Profitability
|
Metric
|
BYSI
|
|---|---|
Return on Assets (Normalized) | −29.23% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BYSI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Q%?^BP | LOCK|^%>% | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@<ZB<r | LOCK|Ch>^ | $84B | |||
| Moderna Inc
MRNA
| LOCK|b<$k@! | LOCK|#Nq | $83B | |||
| argenx SE ADR
ARGX
| LOCK|PM<>?F | LOCK|&mq | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|YR^fnw# | LOCK|^# | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Z<mrzk | LOCK|^mGx | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?Fq!N&hY | LOCK|qq!X< | $29B | |||
| Incyte Corp
INCY
| LOCK|gmWG&m | LOCK|H% | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|Gnp^!$ | LOCK|DM# | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|?&rdVp | LOCK|w! | $14B |
United States